echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Several key studies that must be read in the field of prostate cancer in 2020

    Several key studies that must be read in the field of prostate cancer in 2020

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The European Urological Association (EAU) 2021 Virtual Meeting of Oncology Urology (ESOU) presented a must-read paper on urological oncology from 2020, discussing important papers related to prostate cancer.
    first paper published in the New England Journal of Medicine, "MRI Targeting, Systematic and Joint Biopsies for Prostate Cancer."
    1 paper assessed whether magnetic resonance imaging (MRI) for biopsies could reduce MRI visible lesions in men with incorrect classification of prostate cancer.
    a total of 2,103 men with MRI visible prostate lesions received MRI targeted and systematic biopsies, the main results of which were cancer, according to the hierarchy.
    addition, upgrades and downgrades of the whole tissue pathology analysis from biopsies to surgical specimens were recorded in men who subsequently underwent prostate cancer treatment.
    the authors found that 1,312 (62.4%) of cancers were diagnosed in combination, while 404 men (19.2%) received treatment for prostate cancer.
    the cancer detection rate of MRI-targeted biopsies was significantly lower than that of systematic biopsies, for stage 1 cancers, and significantly higher in groups 3 to 5 (p .lt;0).
    )。
    combined biopsy resulted in 208 more men (9.9 per cent) being diagnosed with cancer than men using either method alone, and upgraded to the senior group of 458 men (21.8 per cent).
    , however, 8.8% of clinically important cancers (≥3 groups) would be misclassified if only MRI target biopsies were performed (see: NEJM:...) MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.